Fig. 7From: Subsets of mononuclear phagocytes are enriched in the inflamed colons of patients with IBDChemokines retain high expression in non-responders after treatment (GSE73661). IFX: infliximab; VDZ: vedolizumab; NR: non-responder; R: responder; B: before treatment (Week 0); A: after treatment (Week 4–6 for infliximab; Week 52 for vedolizumab)Back to article page